Forge Biologics Launches Plasmid DNA Manufacturing Services

Article

Forge Biologics will offer three grades of plasmid manufacturing services at its Columbus, Ohio, location.

Forge Biologics, a contract development and manufacturing organization focused on gene therapies, announced the addition of plasmid DNA manufacturing to its Columbus, Ohio, facility on Sept. 27, 2022. The addition is designed to complement the company’s existing manufacturing services for gene therapy programs, including anti-adeno-virus process development, analytic development, current good manufacturing practice (CGMP) manufacturing, and automated final fill capabilities.

According to a company press release, the plasmid manufacturing services encompass three grades: research-grade, for discovery, research, and development; GMP-pathway, for early stage clinical trial CGMP adeno-associated virus (AAV) manufacturing; and CGMP, for late-stage clinical and commercial CGMP manufacturing. Research-grade and GMP-pathway plasmid grade manufacting is currently available, and CGMP plasmid production is expected to come online in 2023.

“The launch of plasmid DNA manufacturing enables clients to better streamline the production of their AAV programs by vertically integrating plasmids into our manufacturing process,” said John Maslowski, chief commercial officer, Forge Therapeutics, in the release. “The ability to streamline vendor management, better control timeline risks, and accelerate end-to-end AAV manufacturing are important differentiators when upscaling to our 5000-L [C]GMP bioreactors for clients and patients.”

Source: Forge Biologics

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content